옵션 체인은 다양한 행사가격과 만기일에 대한 Humana의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Humana에 대한 시장 심리를 평가합니다..

Humana (NYSE:HUM) 주식, 옵션 체인

HUMANA INC

Humana

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.

Jim Cramer

Government

Health Care

Markets

최근 대중과 규제 당국, 언론의 집중적인 조사를 받고 있는 미국 최대 의료 보험사 유나이티드헬스(NYSE:UNH의 위기 심화에 대해 짐 크레이머가 분석했다.무슨 일 있었나: 목요일(15일) 짐 크레이머는 자신의 소셜미디어 엑스(X) 계정에서 연방 범죄 수사에 대한 월스트리트저널(WSJ)의 보도를 공개적으로 부인한 유나이티드헬스의 문제에 대해 논평했다. 

짐 크레이머, 유나이티드헬스가 범죄 수사 보도 부인하자 &#34;유죄 판결 받게 된다면...&#34;

Meta Platforms Inc. (META)

Equities

Large Cap

Movers

BURL

CRWV

NVDA

RDDT

SMCI

YUMC

유나이티드헬스, 메타 등 지난주 부활절 주간에 급락한 대형주 11종목 (4월 14~18일)

Analyst Color

Earnings Beats

News

Guidance

Analyst Ratings

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

미국의 의료 보험 회사 휴매나(NYSE:HUM)의 주식은 수요일 소폭 상승 마감했다. 화요일 이 회사는 4분기 조정 주당순이익이 2.16달러 손실이라고 발표했다. 이는 전년 대비 11센트 감소한 수치로, 컨센서스와 일치하며 별 등급제에 대한 추가 투자를 포함한 것이다.

휴매나의 2025 전망, 산업 압박에도 불구하고 조심스러운 낙관론을 보여

Humana Inc

Humanscape

Humacyte Inc

Humble & Fume Inc

Hua Medicine

Humm Group Ltd

Humble Energy Inc

Hummingbird Resources PLC

Humatech Inc

<a href="https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19">https://www.wsj.com/politics/policy/lawmakers-seek-to-close-va-loophole-that-funnels-billions-to-private-medicare-insurers-cfbe0b19</a>

CLOV

ELEV

'Lawmakers Seek to Close VA Loophole That Funnels Billions to Private Medicare Insurers'- WSJ

Whales with a lot of money to spend have taken a noticeably bullish stance on Humana.
Looking at options history for Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $84,926 and 6, calls, for a total amount of $1,517,276.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $170.0 to $380.0 for Humana during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Humana's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Humana's substantial trades, within a strike price spectrum from $170.0 to $380.0 over the preceding 30 days.
<h3>Humana Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750701840_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$13.9</td>
<td>$13.4</td>
<td>$13.6</td>
<td>$250.00</td>
<td>$1.3M</td>
<td align="right">173</td>
<td>1.0K</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$23.2</td>
<td>$20.6</td>
<td>$22.43</td>
<td>$260.00</td>
<td>$45.1K</td>
<td align="right">33</td>
<td>20</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$83.6</td>
<td>$82.5</td>
<td>$83.6</td>
<td>$170.00</td>
<td>$33.4K</td>
<td align="right">15</td>
<td>4</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$106.1</td>
<td>$99.0</td>
<td>$103.26</td>
<td>$340.00</td>
<td>$30.9K</td>
<td align="right">0</td>
<td>3</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/21/25</td>
<td>$146.3</td>
<td>$137.4</td>
<td>$142.24</td>
<td>$380.00</td>
<td>$28.4K</td>
<td align="right">2</td>
<td>2</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Having examined the options trading patterns of Humana, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Humana Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 711,531, with HUM's price down by -0.22%, positioned at $239.09.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Humana</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $270.25.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Hold rating on Humana with a target price of $280. 
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Humana, targeting a price of $268. 
&#x2A; An analyst from B of A Securities has decided to maintain their Neutral rating on Humana, which currently sits at a price target of $260. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on Humana with a target price of $273. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Humana with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Looking At Humana's Recent Unusual Options Activity

B of A Securities analyst Kevin Fischbeck maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Neutral and lowers the price target from $320 to $260.

Price Target

B of A Securities Maintains Neutral on Humana, Lowers Price Target to $260

Truist Securities analyst David Macdonald maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Hold and lowers the price target from $305 to $280.

Truist Securities Maintains Hold on Humana, Lowers Price Target to $280

<a href="https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-16/senate-republicans-to-omit-medicare-advantage-cuts-in-tax-bill?embedded-checkout=true</a>

EHTH

GOCO

'Senate Republicans to Omit Medicare Advantage Cuts in Tax Bill'- Bloomberg

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $273 to $268.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $268

Humana's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) short percent of float has risen 11.11% since its last report. The company recently reported that it has 3.44 million shares sold short, which is 3.2% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.8 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Humana Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749499218_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Humana has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Humana's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Humana's peer group average for short interest as a percentage of float is 4.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is Humana Gaining or Losing Market Support?

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) signaled support for reforms that would curb industry billing practices that have led to billions <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in additional payments</a>.
What Happened: Last fall, Senators Mike Crapo and Ron Wyden asked insurers for ideas to address home-visit-related payment practices. 
Human, one of the largest Medicare Advantage insurers in the U.S., recently shared its stance. In a one-page policy overview viewed by The Wall Street Journal, the company favored limiting insurers&#8217; use of home visit diagnoses to obtain higher payments.
These home visits, often conducted by nurse practitioners and not directly linked to treatment, have become increasingly scrutinized for their role in boosting payments by identifying sometimes questionable or unverified medical conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
Why It Matters: Humana&#8217;s position is a notable shift in the ongoing debate over payments tied to diagnosis coding in the $460 billion Medicare Advantage program.
A Wall Street Journal investigation <a target="_blank" href="https://www.wsj.com/health/healthcare/medicare-billing-changes-humana-6f20c05b" rel="noreferrer noopener">revealed</a> that such home-based assessments generated $15 billion in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45108509/humana-does-not-alter-2025-outlook-despite-sales-miss-and-medicare-membership-decline" rel="noreferrer noopener">additional revenue for Medicare</a> Advantage insurers between 2019 and 2021.
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) accounted for roughly two-thirds of those payments, with an average gain of $2,735 per home visit. Humana&#8217;s average was $1,525.
UnitedHealth&#8217;s HouseCalls program conducted around 2.9 million home visits last year, while CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), through Signify Health, also operates a similar model.
Insurers argue that many of these home visits help detect undiagnosed conditions. However, reports indicate that diagnoses are frequently recorded by nurses who aren&#8217;t treating the conditions and may rely on broad training to spot potential health issues.
These diagnoses often don&#8217;t align with those documented by the patients&#8217; primary care physicians.
Humana has proposed that insurers should only receive extra payments for diagnoses made during home visits if those conditions are documented during other types of medical encounters, such as health-risk assessments outside the home or standard clinic visits.
The company also recommends limiting another controversial practice: diagnosis coding from medical chart reviews unrelated to specific patient visits. Humana&#8217;s policy update comes after an internal review launched by CEO Jim Rechtin, who took the helm in July 2023.
Meanwhile, Medicare&#8217;s top official, Mehmet Oz, has committed to tightening oversight of the Advantage program.
Legal Issues: In May, the U.S. Department of Justice filed a lawsuit against <a href="https://www.benzinga.com/general/health-care/25/04/44927473/despite-medicaid-pressure-elevance-health-delivers-strong-q1-performance-reiterates-profit-outlook" target="_blank" rel="noreferrer noopener">Elevance Health, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana, and Aetna, Inc. 
The lawsuit alleges that from 2016 through at least 2021, the insurers paid hundreds of millions of dollars in illegal kickbacks to brokers in exchange for enrolling Medicare beneficiaries into their <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45202124/humana-elevance-aetna-face-doj-lawsuit-over-illegal-kickback-scheme-discrimination-against-disabled-people" rel="noreferrer noopener">Medicare Advantage plans</a>.
And in February, the Justice Department launched a civil fraud investigation into UnitedHealth&#8217;s <a href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" target="_blank" rel="noreferrer noopener">Medicare billing practices</a>.
The probe examines UnitedHealth's Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Price Action: HUM stock is up 0.29% at $231.88 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45791411/procter-gamble-to-eliminate-7000-roles-divest-brands-in-new-restructuring-strategy" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble To Eliminate 7,000 Roles, Divest Brands In New Restructuring Strategy</a></li>
</ul>
Image: Shutterstock

Humana Backs Reforms To Limit Medicare Advantage Billing Practices

Agreement Expanded for Additional Five Years
PALM BEACH GARDENS, Fla., June 3, 2025 /PRNewswire/ -- Longevity Health, a clinical services company and national Institutional Special Needs Plan (ISNP), today announced that it has extended its partnership with Humana through 2030.
Launched in 2023, the Humana/Longevity collaboration expands special needs health plan offerings for Medicare-eligible individuals living in skilled nursing and senior living facilities. The collaboration between the two companies currently serves members in seven states, and there are plans for significant expansion of new markets, solutions, customer segments and members served.

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Extends Strategic Partnership With Humana Through 2030 To Expand Special Needs Medicare Plan Offerings Across Skilled Nursing And Senior Living Facilities, With Plans For Multi-State Growth And Broader Member Reach

Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $307.44, a high estimate of $326.00, and a low estimate of $273.00. Witnessing a positive shift, the current average has risen by 3.69% from the previous average price target of $296.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748887257_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Humana. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$273.00</td>
<td>$322.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$305.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$290.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Michael Wiederhorn</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$310.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$322.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$325.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Jason Cassorla</td>
<td>Guggenheim</td>
<td>Announces</td>
<td>Buy</td>
<td>$326.00</td>
<td>-</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$316.00</td>
<td>$305.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Humana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Humana compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Humana's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Humana's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HUM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Humana analyst ratings.</a>
<h2>Delving into Humana's Background</h2>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
<h3>Humana: Delving into Financials</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Humana's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 8.45% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Humana's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 3.87%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.29%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Humana's ROA stands out, surpassing industry averages. With an impressive ROA of 2.55%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Humana's debt-to-equity ratio is below the industry average. With a ratio of 0.75, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: Simplified</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 9 Analyst Projections For Humana

Barclays analyst Andrew Mok maintains Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) with a Equal-Weight and lowers the price target from $322 to $273.

Barclays Maintains Equal-Weight on Humana, Lowers Price Target to $273

Members of Humana Inc.'s (the "Company") senior management team are scheduled to meet with investors and analysts at various meetings between June 2, 2025 and June 30, 2025. During these meetings, the Company intends to reaffirm its guidance of approximately $14.68 in diluted earnings per common share ("EPS") or approximately $16.25 in adjusted earnings per common share ("Adjusted EPS"), in each case for the year ending December 31, 2025 ("FY 2025"). This guidance is consistent with the guidance issued in the Company's press release dated April 30, 2025.
 &nbsp;

Humana Reaffirms FY25 Guidance Of $14.68 EPS And $16.25 Adj EPS

Financing

Humana Enters Into $5B Unsecured Revolving Credit Agreement; Agreement Permits Up To $1B Of Incremental Commitments; New Agreement Replaces Existing $2.1B Credit Agreement

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 29 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 31% bearish. Among these notable options, 11 are puts, totaling $575,520, and 18 are calls, amounting to $1,092,502.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $370.0 for Humana, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humana's significant trades, within a strike price range of $200.0 to $370.0, over the past month.
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748458863_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$245.00</td>
<td>$216.8K</td>
<td align="right">27</td>
<td align="right">310</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$16.0</td>
<td>$14.8</td>
<td>$15.8</td>
<td>$235.00</td>
<td>$185.4K</td>
<td align="right">85</td>
<td align="right">251</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$250.00</td>
<td>$122.1K</td>
<td align="right">517</td>
<td align="right">174</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$25.9</td>
<td>$25.7</td>
<td>$25.7</td>
<td>$240.00</td>
<td>$105.3K</td>
<td align="right">111</td>
<td align="right">42</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.6</td>
<td>$8.9</td>
<td>$9.6</td>
<td>$222.50</td>
<td>$96.0K</td>
<td align="right">40</td>
<td align="right">160</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.
<h3>Current Position of Humana</h3>
<ul>
<li>Trading volume stands at 992,527, with HUM's price up by 0.96%, positioned at $228.79.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 63 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $301.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $290. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Humana, maintaining a target price of $305. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Humana, maintaining a target price of $310. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

This Is What Whales Are Betting On Humana

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/30/25</td>
<td>$65.00</td>
<td>$37.4K</td>
<td>872</td>
<td>1.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$70.00</td>
<td>$302.0K</td>
<td>5.1K</td>
<td>1.1K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$850.00</td>
<td>$33.5K</td>
<td>31.4K</td>
<td>798</td>
</tr>
<tr>
<td>VERA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$30.00</td>
<td>$41.1K</td>
<td>446</td>
<td>342</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$400.00</td>
<td>$33.4K</td>
<td>1.9K</td>
<td>282</td>
</tr>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$65.00</td>
<td>$104.7K</td>
<td>114</td>
<td>162</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$180.00</td>
<td>$111.8K</td>
<td>2.1K</td>
<td>105</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$215.00</td>
<td>$54.2K</td>
<td>385</td>
<td>87</td>
</tr>
<tr>
<td>VRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$80.00</td>
<td>$28.8K</td>
<td>50</td>
<td>40</td>
</tr>
<tr>
<td>ONC</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$220.00</td>
<td>$32.2K</td>
<td>0</td>
<td>15</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a put option trade with neutral sentiment. It expires in 3 day(s) on May 30, 2025. Parties traded 170 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $37.4K, with a price of $220.0 per contract. There were 872 open contracts at this strike prior to today, and today 1645 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a put option trade that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 1000 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $302.0K, with a price of $302.0 per contract. There were 5187 open contracts at this strike prior to today, and today 1108 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 100 contract(s) at a $850.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $33.5K, with a price of $335.0 per contract. There were 31403 open contracts at this strike prior to today, and today 798 contract(s) were bought and sold. 
• For VERA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>), we notice a put option sweep that happens to be bullish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 34 contract(s) at a $30.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $41.1K, with a price of $1210.0 per contract. There were 446 open contracts at this strike prior to today, and today 342 contract(s) were bought and sold. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a call option trade that happens to be bullish, expiring in 598 day(s) on January 15, 2027. This event was a transfer of 10 contract(s) at a $400.00 strike. The total cost received by the writing party (or parties) was $33.4K, with a price of $3342.0 per contract. There were 1906 open contracts at this strike prior to today, and today 282 contract(s) were bought and sold. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 570 day(s) on December 18, 2026. This event was a transfer of 161 contract(s) at a $65.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $104.7K, with a price of $655.0 per contract. There were 114 open contracts at this strike prior to today, and today 162 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option trade with bearish sentiment. It expires in 80 day(s) on August 15, 2025. Parties traded 87 contract(s) at a $180.00 strike. The total cost received by the writing party (or parties) was $111.8K, with a price of $1286.0 per contract. There were 2152 open contracts at this strike prior to today, and today 105 contract(s) were bought and sold. 
• Regarding HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we observe a put option sweep with bullish sentiment. It expires in 24 day(s) on June 20, 2025. Parties traded 67 contract(s) at a $215.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $54.2K, with a price of $810.0 per contract. There were 385 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For VRNA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNA#NASDAQ">VRNA</a>), we notice a put option sweep that happens to be bearish, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 40 contract(s) at a $80.00 strike. This particular put needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $28.8K, with a price of $720.0 per contract. There were 50 open contracts at this strike prior to today, and today 40 contract(s) were bought and sold. 
• For ONC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), we notice a call option trade that happens to be neutral, expiring in 24 day(s) on June 20, 2025. This event was a transfer of 15 contract(s) at a $220.00 strike. The total cost received by the writing party (or parties) was $32.2K, with a price of $2150.0 per contract. There were 0 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

VERA

VRNA

10 Health Care Stocks Whale Activity In Today's Session

WIIM

ALHC

Shares of health insurance stocks are trading lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.

<h2>CMS Rolls Out Aggressive Strategy to Enhance and Accelerate Medicare Advantage Audits</h2>

Biotech

'CMS Rolls Out Aggressive Strategy To Enhance And Accelerate Medicare Advantage Audits; Agency Will Begin Auditing All Eligible Medicare Advantage Contracts Each Payment Year And Add Resources To Expedite Completion Of 2018 To 2024 Audits'

Legal

Press Releases

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Humana Inc. (NYSE: HUM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces the Investigation of Humana Inc. (NASDAQ: HUM) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

Comments

Humana

Humana (HUM) 옵션

Humana (NYSE:HUM) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌